The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival. The once-popular DNA-testing site will also halt work on therapies it ...
Tempus AI agreed to buy genetic testing company Ambry Genetics for $375 million in cash and $225 million in shares. Chicago-based Tempus, which makes AI-enabled precision medicine solutions ...
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival. The once-popular DNA-testing site will also halt work on therapies it was ...